Tohoku J. Exp. Med., 2023 September, 261(1)

Common Blood Test Indices for Predicting Transient Abnormal Myelopoiesis-Related Mortality in Infants with Down Syndrome

Hideyuki Hawaka,1 Tomoyuki Shimokaze,1 Tomoko Yokosuka,2 Katsuaki Toyoshima,1 Tomoko Saito1 and Hiroaki Goto2

1Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
2Department of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan

Transient abnormal myelopoiesis (TAM) can cause early death in children with Down syndrome, and liver failure is the most common cause of death. The aim of this single-center retrospective study was to identify a quantitative index for predicting TAM-related mortality at the time of diagnosis. Of the 462 children with Down syndrome admitted to our hospital from 1992 to 2021, we studied 12 infants with TAM-related death and 31 survivors who were diagnosed with TAM. In the death and survival groups, the median gestational ages were 34.9 and 37.1 weeks, respectively (p = 0.12). At diagnosis, the white blood cell (WBC) counts were 99.2 and 36.2 × 109/L (p = 0.011), the hemoglobin concentrations were 131 and 159 g/L (p = 0.009), and the serum albumin concentrations were 23 and 31 g/L (p < 0.001), respectively. The areas under the receiver operating characteristic curve for the abilities of the WBC count, hemoglobin, and serum albumin at diagnosis to predict survival were 0.75, 0.76, and 0.85, respectively. The serum albumin concentration threshold of 28 g/L at diagnosis had sensitivity of 0.79 and specificity of 0.82. Gestational age and serum albumin concentration were entered into a logistic regression model. The serum albumin concentration was an independent indicator of TAM-related death (adjusted odds ratio, 0.78; 95% confidence interval, 0.65-0.93; p = 0.005). In conclusion, a low serum albumin concentration at diagnosis may be a good predictor of TAM-related death.

Key words —— albumin; disseminated intravascular coagulation; Down syndrome; liver failure; transient leukemia

===============================

Tohoku J. Exp. Med., 2023 September, 261(1), 51-56.

Correspondence: Hideyuki Hawaka, Department of Neonatology, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa, Minami-ku, Yokohama, Kanagawa 232-8555, Japan.

e-mail: h.hawaka0831@gmail.com